Posted by Michael Wonder on 13 Nov 2016
Additional public summary documents from the PBAC July 2016 meeting
11 November 2016 - Additional public summary documents from the PBAC July 2016 meeting are now available.
The additional documents are for first-time rejections and deferrals. There is a public summary document for the initial submission for nivolumab (Opdivo) for use by patients with renal cell carcinoma which reveals its PBAC outcome for the first time.
The MAESTrO Database has been updated to account for the publication of additional information on comparators, primary outcomes, patient reported outcomes and economic models.
